Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report serves as a regulatory update regarding the company's investigational drug, albiglutide, a once-weekly treatment for adult patients with type 2 diabetes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the extension of the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide. The date has been extended by three months to April 15, 2014, to allow the FDA time for a full review of information submitted by GSK in response to regulatory requests.
Guidance, Outlook, and Risks
- Regulatory Status: Albiglutide is not currently approved for use anywhere in the world. The US Biologics Licence Application was submitted on January 14, 2013, and the European Medicines Agency (EMA) Marketing Authorisation Application was submitted on March 7, 2013.
- Outlook: The EMA filing is progressing to schedule, while the US review timeline has been adjusted.
- Risks: GSK includes a cautionary statement that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Specific risk factors are referenced in the company's 2012 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the new PDUFA decision date of April 15, 2014, for albiglutide.
- Confirm the status of the EMA Marketing Authorisation Application, which is reported as on schedule.
- Review the specific FDA information requests that necessitated the three-month extension.
- Consult the 2012 Form 20-F for detailed risk factors affecting GSK's operations.